Please find enclosed the Outcome of the Board Meeting held on May 07, 2026, inter alia, for the approval of the Financial Results for the quarter and financial year ended March 31, 2026, ....
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies Ltd reported strong financial performance for FY2026 with revenue from operations growing 22.3% to Rs. 774.27 Crores from Rs. 633.10 Crores in FY2025. Profit after tax increased 55.3% to Rs. 148.81 Crores compared to Rs. 95.78 Crores in the previous year. The Board recommended a final dividend of Rs. 7 per equity share, bringing total dividend for FY2026 to Rs. 9.33 per share (post-bonus adjustment). The company also announced a change in statutory auditors, appointing Price Waterhouse Chartered Accountants LLP for a 5-year term, replacing MSKA & Associates LLP. Two new non-executive directors were appointed while two directors resigned. The Board approved investment of up to Rs. 5.5 Crores in Think Health Diagnostics Private Limited, a wholly owned subsidiary, and proposed amendments to the Memorandum of Association to expand business activities.
Strong financial results with 22% revenue growth and 55% PAT growth indicate healthy business momentum. The dividend payout and auditor change are routine corporate actions with minimal impact on stock price.